Tango Therapeutics TNGX Vopimetostat Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported vopimetostat direct program expenses-rd — research and development expense of $9.33M in Q1 2026.
- How has Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense increased by 70.9% year-over-year, from $5.46M to $9.33M.
- What does vopimetostat direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development costs specifically allocated to the Vopimetostat clinical program. It captures the investment required for preclinical studies, clinical trials, and manufacturing development associated with this specific therapeutic candidate. Tracking these costs allows investors to evaluate the capital intensity and progress of the company's lead precision oncology assets.